A Multiple-Dose Study of Blockade of Subjective Opioid Effects, Plasma Levels, and Safety of Subcutaneous Injections of Depot Buprenorphine (RBP-6000) in Subjects With Opioid Use Disorder
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2018
Price : $35 *
At a glance
- Drugs Buprenorphine (Primary) ; Hydromorphone
- Indications Opioid abuse
- Focus Pharmacodynamics
- Sponsors Reckitt Benckiser
- 08 Dec 2015 Results published in the Journal of Clinical Psychopharmacology
- 13 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Sep 2014 Planned End Date changed from 1 Jul 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.